Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Unresectable Solid Tumor

Unresectable Solid Tumor

4

Pipeline Programs↗

4

Active Trials↗

7

Companies Involved↗

Unresectable Solid Tumor is an early-stage landscape with 4 programs across 7 companies.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

89/100

Attrition Rate

9/100

Pipeline

Programs by Phase

Preclinical

No programs

Phase 11

CAR-T/CAR-NK Cells

The Second Hospital of Shandong University

Phase 23

Berzosertib

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Avelumab

EMD Serono

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

4programs

Monoclonal antibody250%

Small molecule125%

Cell therapy125%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

33

clinical trials

Completed25 · 76%

Active, not recruiting4 · 12%

Terminated3 · 9%

Unknown status1 · 3%

Clinical Trials

Trial Activity

33 trials

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04957615·16 enrolled

Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable Solid Tumors

Active, not recruiting·TThe Second Hospital of Shandong University·Phase 1·NCT06572956·10 enrolled

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04266912·23 enrolled

A Phase I Trial of Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy

Active, not recruiting·WWashington University School of Medicine·Preclinical·NCT05831579·24 enrolled

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·National Cancer Institute (NCI)·Phase 1·NCT00089362·30 enrolled

Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·MMayo Clinic·Phase 1·NCT00005068

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor

Completed·National Cancer Institute (NCI)·Phase 1·NCT00087217·35 enrolled

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Completed·PPharmaMar·Phase 1·NCT01970540·122 enrolled

GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·National Cancer Institute (NCI)·Phase 1·NCT00078962·40 enrolled

Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·UUniversity Health Network, Toronto·Phase 1·NCT00126620·17 enrolled

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

Completed·PPharmaMar·Phase 1·NCT01970553·47 enrolled

Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors

Completed·National Cancer Institute (NCI)·Phase 1·NCT00074321·84 enrolled

Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00368914·30 enrolled

UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·National Cancer Institute (NCI)·Phase 1·NCT00042861

Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00238225·15 enrolled

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)